Traduction de «delayed » (Français → Néerlandais) :

DGF Delayed Graft Function = Fonction « retardée » et surtout insuffisante de l’organe transplanté.
DGF Delayed Graft Function = “vertraagd” op gang komende en vooral onvoldoende functie van het getransplanteerde orgaan.

Ten Consequences of AIDS Treatment Delayed, Deferred or Denied | Médecins Sans Frontières
Ten Consequences of AIDS Treatment Delayed, Deferred or Denied | Artsen Zonder Grenzen

8.2.2.2 Inequalities in the indicators of accessibility The percentage of households reporting to have delayed contacts with the health system for financial reasons was strongly related to the income level, with 27% of delay in the households of the lowest quintile versus 4%
114 These data are not presented in detail in this report. 8.2.2.2 Inequalities in the indicators of accessibility The percentage of households reporting to have delayed contacts with the health system for financial reasons was strongly related to the income level, with 27% of delay in the households of the lowest quintile versus 4%

Accueil | Actualités | Ten Consequences of AIDS Treatment Delayed, Deferred or Denied
Home | Actueel | Ten Consequences of AIDS Treatment Delayed, Deferred or Denied

Traitement médicamenteux de la sclérose en plaques (Idées-Forces tirées de La Revue Prescrire jusqu’au n°293 (mars 2008)] La Revue Prescrire 2008; 28:288-93 Clerico M , Faggiano F, Palace J, Rice G, Tintorè M et Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
Traitement médicamenteux de la sclérose en plaques (Idées-Forces tirées de la Revue Prescrire jusqu’au n°293 (mars 2008)] La Revue Prescrire 2008; 28:288-93 Clerico M, Faggiano F, Palace J, Rice G, Tintorè M en Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Liste des abréviations utilisées ADN Acide désoxyribonucléique AST Aspartate amino transférase CI Cold ischemia CIT Cold ischemia time CSS Conseil Supérieur de la Santé DBD Donation after brain death or HBD DCD Donation after cardiac death or NHBD DGF Delayed graft function EC EuroCollins ECD Extended/expanded criteria donors ECMO Extracorporeal membrane oxygenation EVLP Ex vivo lung perfusion HBD Heart-beating donors or DBD HMP Hypothermic machine perfusion HOPE Hypothermic oxygenated perfusion HTK Histidine-tryptophane-ketoglutarate IRI Ischemia-reperfusion injury ISHLT International Society for Heart and Lung Transplantation L-FABP Liver type fatty acid-binding protein MP Machine perfusion NHBD Non-heart-beating donors NMP Normothermic machine perfusion OCS Organ case system OTS Organ transport system PEG Polyéthylène glycol PFC Perfluorocarbones PNF Primary non-function PGD Primary graft dysfunction QALY Quality-adjusted life years SCD Standard criteria donor SCS Static or simple cold storage SCOT® Solution de conservation d’organes et de tissus
Lijst van de gebruikte afkortingen ASAT Aspartaat-aminotransferase CI Cold ischemia CIT Cold ischemia time DBD Donation after brain death or HBD DCD Donation after cardiac death or NHBD DGF Delayed graft function DNA Desoxyribonucleïnezuur EC EuroCollins ECD Extended/expanded criteria donors ECMO Extracorporeal membrane oxygenation EVLP Ex vivo lung perfusion HBD Heart-beating donors or DBD HGR Hoge Gezondheidsraad HMP Hypothermic machine perfusion HOPE Hypothermic oxygenated perfusion HTK Histidine-tryptophane-ketoglutarate IRI Ischemia-reperfusion injury ISHLT International Society for Heart and Lung Transplantation L-FABP Liver type fatty acid-binding protein Long-Tx Longtransplantatie MP Machine perfusion NHBD Non-heart-beating donors NMP Normothermic machine perfusion OCS Organ case system OTS Organ transport system PEG Polyethyleenglycol PFK Perfluorkoolwaterstoffen PGD Primary graft dysfunction PNF Primary non-function QALY Quality-adjusted life years SCD Standard criteria donor SCOT® Solution de conservation d’organes et de tissus

Les organes de donneurs DCD présentaient traditionnellement des taux plus élevés de PNF, delayed graft function (DGF) et une moindre survie à long terme du greffon (Moers et al., 2007).
De organen van DCD-donoren zouden traditioneel hogere incidenties van PNF, delayed graft function (DGF) en op lange termijn een slechtere overleving van het transplantaat vertonen (Moers et al., 2007) (zie definitie bijlage 5.1).

El-Daher NT, Hijazi S, Tawasdeh N. Immediate versus delayed treatment of group A beta-hemolytic streptococcal pharyngitis with penicillin-V. Ped Inf Dis J 1991; 10:126-30.
El-Daher NT, Hijazi S, Tawasdeh N. Immediate versus delayed treatment of group A beta-hemolytic streptococcal pharyngitis with penicillin-V. Ped Inf Dis J 1991; 10:126-30.

Distinct energy programmation during brady-pacing and post shock Programmable minimal and maximal heart rate Activity sensor and rate response Rate Hysteresis Programmable AV delay after atrial sense or pace Anti-PMT algorithm Defibrillation Defibrillation or ATP VT/SVT discrimination algorithms Event Counters Heart Rate time interval diagnostics Stored intracardiac electrograms Distinct programmation of right/left ventricular stimulation 4 years warranty on longevity 3 years warranty on longevity
Distinct energy programmation during brady-pacing and post shock Programmable minimal and maximal heart rate Activity sensor and rate response Rate Hysteresis ProgrammableAV delay after atrial sense or pace Anti-PMT algorithm Defibrillation Defibrillation or ATP VT/SVT discrimination algorithms Event Counters Heart Rate time interval diagnostics Stored intracardiac electrograms Distinct programmation of right/left ventricular stimulation 4 years warranty on longevity 3 years warranty on longevity

Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties related to the acquisition of King by Pfizer that could cause results to differ from expectations include: uncertainties as to the timing of the merger; the possibility that a governmental entity may prohibit or delay the consummation of the merger; and the risk of shareholder litigation, including the disposition of currently pending litigation, in connection with the merger.
Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties.